Johns Hopkins Kidney Cancer Program
COLLABORATION, COMPASSION, AND CUTTING EDGE
Johns Hopkins is on the forefront of kidney cancer research and our physicians are leaders in their field who offer the latest treatments and innovations.
The role of surveillance
The Management of Small Renal Masses and Kidney Cancer
Earlier detection of small renal masses has led to new treatment options for kidney cancer. Watch Johns Hopkins urologist Phil Pierorazio, M.D., as he discusses advances in the diagnosis and treatment of the small renal mass.
Active Surveillance For Renal Masses: Where Are We In 2016?
Phillip M. Pierorazio, MD, Assistant Professor of Urology and Oncology, Brady Urological Institute, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland asks the question Active Surveillance For Renal Masses: Where Are We In 2016? at the 2016 annual International Kidney Cancer Symposium.
Phase 3 Perioperative Nivolumab in M0 RCC (PROSPER RCC, ECOG –ACRIN 8143) A UROLOGIST’S PERSPECTIVE
Mohamad E. Allaf, MD, Associate Professor of Urology, Oncology, & BME MEA Endowed Director, Minimally Invasive Surgery Johns Hopkins Medicine presents Phase 3 Perioperative Nivolumab in M0 RCC (PROSPER RCC, ECOG –ACRIN 8143) A UROLOGIST’S PERSPECTIVE at the 2016 annual International Kidney Cancer Symposium.
|JOHNS HOPKINS HOSPITAL:
Mohamad E. Allaf, MD
Trinity Bivalacqua, MD,PhD
Misop Han, MD
Phillip M. Pierorazio, M.D.
Michael Johnson , M.D.
|JOHNS HOPKINS BAYVIEW MEDICAL CENTER:
Christian Pavlovich, MD
Stephen Schatz, MD
SIBLEY MEMORIAL HOSPITAL
Armine K. Smith, M.D.
Pedram Argani, MD